Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study

Pfizer, Inc. PFE announced promising data from an early-stage study on its investigational gene therapy for the treatment of Duchenne muscular dystrophy (DMD), a rare muscular degenerative disease. However, further dosing in the study has been stopped as serious side effects were observed in two participants in the study.